ImClone kept at sell by Merrill

Merrill Lynch analyst Eric Ende maintained ImClone Systems Inc. at a sell. The Food and Drug Administration approved Amgen's Vectibix for colorectal cancer. The drug is expected to capture as much as 60% of ImClone's Erbitux market. Lower pricing caused the analyst to reduce 2007 Erbitux sales estimates to $689 million from $787 million. Shares of the New York City-based biopharmaceutical company were down 24 cents, or 0.83%, at $28.51. (Nasdaq: IMCL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.